{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:45:56Z","timestamp":1787316356948,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40261-024-01368-w","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:49:16Z","timestamp":1724410156000},"page":"655-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8637-3235","authenticated-orcid":false,"given":"Rafaela","family":"de Moraes-Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9646-8460","authenticated-orcid":false,"given":"Regina","family":"Chahine Chater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5448-8190","authenticated-orcid":false,"given":"Izabela","family":"Pera Calvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8607-6302","authenticated-orcid":false,"given":"Yasmin","family":"Mesquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2215-3801","authenticated-orcid":false,"given":"Rubiana","family":"Sarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1972-3922","authenticated-orcid":false,"given":"Izadora","family":"Lapenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-6687","authenticated-orcid":false,"given":"L\u00edvia","family":"Figueiredo Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1014-0923","authenticated-orcid":false,"given":"Luana","family":"Moury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-6628","authenticated-orcid":false,"given":"Pedro","family":"Herranz-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"19","key":"1368_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, Clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"1368_CR2","unstructured":"World Health Organization. Global report on psoriasis. 2016. https:\/\/iris.who.int\/handle\/10665\/204417. Accessed on 27 Dec 27."},{"issue":"2","key":"1368_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205\u201312. https:\/\/doi.org\/10.1111\/jdv.13854.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10281","key":"1368_CR4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6.","journal-title":"Lancet"},{"issue":"3","key":"1368_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-2133.2007.08307.x","volume":"158","author":"E Christophers","year":"2008","unstructured":"Christophers E. Explaining phenotype heterogeneity in patients with psoriasis. Br J Dermatol. 2008;158(3):437\u201341. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08307.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1368_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4103\/2229-5178.209622","volume":"8","author":"R Torsekar","year":"2017","unstructured":"Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8(4):235\u201345. https:\/\/doi.org\/10.4103\/2229-5178.209622.","journal-title":"Indian Dermatol Online J"},{"issue":"9","key":"1368_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/1744666X.2023.2219897","volume":"19","author":"A Drakos","year":"2023","unstructured":"Drakos A, Vender R, Torres T. Topical roflumilast for the treatment of psoriasis. Expert Rev Clin Immunol. 2023;19(9):1053\u201362. https:\/\/doi.org\/10.1080\/1744666X.2023.2219897.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"1368_CR8","doi-asserted-by":"publisher","first-page":"734","DOI":"10.36849\/JDD.2020.5370","volume":"19","author":"KA Papp","year":"2020","unstructured":"Papp KA, Gooderham M, Droege M, et al. Roflumilast cream improves signs and symptoms of plaque psoriasis: results from a phase 1\/2a randomized, controlled study. J Drugs Dermatol. 2020;19(8):734\u201340. https:\/\/doi.org\/10.36849\/JDD.2020.5370.","journal-title":"J Drugs Dermatol"},{"key":"1368_CR9","doi-asserted-by":"publisher","first-page":"CD005028","DOI":"10.1002\/14651858.CD005028.pub3","volume":"3","author":"AR Mason","year":"2013","unstructured":"Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;3:CD005028. https:\/\/doi.org\/10.1002\/14651858.CD005028.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1368_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4103\/2229-5178.142483","volume":"5","author":"A Coondoo","year":"2014","unstructured":"Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5(4):416\u201325. https:\/\/doi.org\/10.4103\/2229-5178.142483.","journal-title":"Indian Dermatol Online J"},{"issue":"2","key":"1368_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/1574886315666200128095958","volume":"15","author":"H Bakshi","year":"2020","unstructured":"Bakshi H, Nagpal M, Singh M, Dhingra GA, Aggarwal G. Treatment of psoriasis: a comprehensive review of entire therapies. Curr Drug Saf. 2020;15(2):82\u2013104. https:\/\/doi.org\/10.2174\/1574886315666200128095958.","journal-title":"Curr Drug Saf"},{"key":"1368_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2023.09.005","author":"M Mansilla-Polo","year":"2023","unstructured":"Mansilla-Polo M, Gimeno E, Morgado-Carrasco D. Roflumilast t\u00f3pico y oral en dermatolog\u00eda Una revisi\u00f3n narrativa. Actas Dermosifiliogr. 2023. https:\/\/doi.org\/10.1016\/j.ad.2023.09.005. (Published online September 12, 2023).","journal-title":"Actas Dermosifiliogr"},{"key":"1368_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/PTT.S303634","volume":"11","author":"M Milakovic","year":"2021","unstructured":"Milakovic M, Gooderham MJ. Phosphodiesterase-4 inhibition in psoriasis. Psoriasis (Auckl). 2021;11:21\u20139. https:\/\/doi.org\/10.2147\/PTT.S303634. (Published 2021 Mar 17).","journal-title":"Psoriasis (Auckl)."},{"issue":"3","key":"1368_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2000073","volume":"383","author":"MG Lebwohl","year":"2020","unstructured":"Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2000073.","journal-title":"N Engl J Med"},{"issue":"11","key":"1368_CR15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2022.15632","volume":"328","author":"MG Lebwohl","year":"2022","unstructured":"Lebwohl MG, Kircik LH, Moore AY, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022;328(11):1073\u201384. https:\/\/doi.org\/10.1001\/jama.2022.15632.","journal-title":"JAMA"},{"issue":"4","key":"1368_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/bjd\/ljad182","volume":"189","author":"LH Kircik","year":"2023","unstructured":"Kircik LH, Alonso-Llamazares J, Bhatia N, et al. Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study. Br J Dermatol. 2023;189(4):392\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljad182.","journal-title":"Br J Dermatol"},{"key":"1368_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71. (Published 2021 Mar 29).","journal-title":"Br Med J"},{"key":"1368_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"Br Med J"},{"issue":"9","key":"1368_CR19","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","volume":"26","author":"PH Schafer","year":"2014","unstructured":"Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016\u201329. https:\/\/doi.org\/10.1016\/j.cellsig.2014.05.014.","journal-title":"Cell Signal"},{"issue":"5","key":"1368_CR20","doi-asserted-by":"publisher","first-page":"22608","DOI":"10.5070\/D3205022608","volume":"20","author":"F Moustafa","year":"2014","unstructured":"Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20(5):22608.","journal-title":"Dermatol Online J"},{"issue":"12","key":"1368_CR21","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.str.2004.10.004","volume":"12","author":"GL Card","year":"2004","unstructured":"Card GL, England BP, Suzuki Y, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure. 2004;12(12):2233\u201347. https:\/\/doi.org\/10.1016\/j.str.2004.10.004.","journal-title":"Structure"},{"issue":"1","key":"1368_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2015.03.049.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1368_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.12788\/cutis.0701","volume":"111","author":"NP Del Toro","year":"2023","unstructured":"Del Toro NP, Wu JJ, Han G. New treatments for psoriasis: an update on a therapeutic frontier. Cutis. 2023;111(2):101\u20134. https:\/\/doi.org\/10.12788\/cutis.0701.","journal-title":"Cutis"},{"issue":"8","key":"1368_CR24","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1177\/10600280221137750","volume":"57","author":"JN Pixley","year":"2023","unstructured":"Pixley JN, Schaetzle T, Feldman SR. A review of topical roflumilast for the treatment of plaque psoriasis. Ann Pharmacother. 2023;57(8):966\u20139. https:\/\/doi.org\/10.1177\/10600280221137750.","journal-title":"Ann Pharmacother"},{"key":"1368_CR25","unstructured":"Arcutis Biotherapeutics, Inc. ZORYVE\u00ae (roflumilast) cream, prescribing information. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; January 2024. https:\/\/www.arcutis.com\/wp-content\/uploads\/USPI-roflumilast-cream.pdf. Accessed on 3 May 2024."},{"key":"1368_CR26","unstructured":"Arcutis Canada, Inc. ZORYVE\u2122 (roflumilast cream) product monograph including patient medication information. North York, ON: Arcutis Canada, Inc.; November 7, 2023. https:\/\/www.arcutis.ca\/wp-content\/uploads\/zoryve-product-monograph.pdf. Accessed on 3 May 2024."},{"key":"1368_CR27","unstructured":"Arcutis Biotherapeutics, Inc. ZORYVE\u00ae (roflumilast) topical foam, 0.3%, prescribing information. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; December 2023. https:\/\/www.arcutis.com\/wp-content\/uploads\/zoryve-foam-pi-hcp.pdf. Accessed on 3 May 2024."},{"issue":"6","key":"1368_CR28","doi-asserted-by":"publisher","DOI":"10.25251\/skin.6.supp.57","volume":"6","author":"LK Ferris","year":"2022","unstructured":"Ferris LK, Armstrong AW, Del Rosso J, Draelos ZD, Gooderham M, Lebwohl M, Papp KA, Soung J, Stein-Gold L, Krupa D, Higham RC, Burnett P, Berk DR. Efficacy and tolerability of roflumilast cream 0.3% in patients with chronic plaque psoriasis involvement on the face, intertriginous, or genital areas: pooled results from Phase 3 trials (DERMIS-1 and DERMIS-2). SKIN J Cutan Med. 2022;6(6): s57. https:\/\/doi.org\/10.25251\/skin.6.supp.57.","journal-title":"SKIN J Cutan Med."},{"issue":"4","key":"1368_CR29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2133.2004.06174.x","volume":"151","author":"CL Carroll","year":"2004","unstructured":"Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151(4):895\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.06174.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1368_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/reum.2018.80718","volume":"56","author":"K Dopytalska","year":"2018","unstructured":"Dopytalska K, Sobolewski P, B\u0142aszczak A, Szyma\u0144ska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018;56(6):392\u20138. https:\/\/doi.org\/10.5114\/reum.2018.80718.","journal-title":"Reumatologia"},{"issue":"1","key":"1368_CR31","doi-asserted-by":"publisher","first-page":"2287401","DOI":"10.1080\/09546634.2023.2287401","volume":"35","author":"B Strober","year":"2024","unstructured":"Strober B, Duffin KC, Lebwohl M, et al. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry. J Dermatolog Treat. 2024;35(1):2287401. https:\/\/doi.org\/10.1080\/09546634.2023.2287401.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1368_CR32","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/j.jaad.2023.07.1048","volume":"90","author":"PV Engel","year":"2024","unstructured":"Engel PV, Smith B, Javadi SS, Wu JJ. It is time to consider a new topical algorithm for psoriasis. J Am Acad Dermatol. 2024;90(2):e84\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.1048.","journal-title":"J Am Acad Dermatol"},{"key":"1368_CR33","unstructured":"Roflumilast (Zoryve): CADTH Reimbursement Recommendation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; September 2023."},{"key":"1368_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.030","author":"L Stein Gold","year":"2024","unstructured":"Stein Gold L, Adam DN, Albrecht L, et al. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.030. (Published online March 29, 2024).","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01368-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01368-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01368-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T20:05:46Z","timestamp":1728158746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01368-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1368"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01368-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"14 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rafaela de Moraes-Souza, Regina Chahine Chater, Izabela Pera Calvi, Yasmin Mesquita, Rubiana Sarto, Izadora Lapenda, L\u00edvia Figueiredo Pereira, Luana Moury, and Pedro Herranz-Pinto have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available within the material of this article and the supplementary material.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Study concept and design: RMS and RCC. Acquisition, analysis, or interpretation of data: RMS, RCC, IPC, and YM. Drafting of the manuscript: RMS and RCC. Critical revision of the manuscript: RMS, RCC, IPC, YM, RS, IL, LFP, LM, and PH. Study supervision: PH. All authors have read and approved the final version of this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}